Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high3,335.75 20/03/17
52 week low1,686.50 23/05/16
52 week change 1,408.00 (82.34%)
4 week volume124,201 27/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech Ltd

Panmure Gordon today reaffirms its buy investment rating on Hutchison China Meditech Ltd (LON:HCM) and raised its...

Chi-Med Presents Clinical Data at ASCO 2017

RNS Number: 5131F Hutchison China Meditech Limited 18 May 2017 Press Release Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting - FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oralpresentation- - Five abstracts in total accepted for fruquintinib, savolitinib andsulfatinib- London: Thursday, May 18, 2017: Hutchison China Med...

Total Voting Rights

RNS Number: 7219D Hutchison China Meditech Limited 28 April 2017 Total Voting Rights London: Friday , April 28, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary shares of US$1.00 each, with...

Results of Annual General Meeting

RNS Number: 5842D Hutchison China Meditech Limited 27 April 2017 Results of Annual General Meeting London: Thursday, April 27, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2017 were duly passed. T...

Why Shell was kicked out of this top-performing portfolio

This portfolio has returned 275% since 2010; David Brenchley finds out which potential "money-making machine" has mo...

Chi-Med present pre-clinical data at AACR

Hutchison China MediTech presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Ca...

Pre-clinical Data Presented at AACR

RNS Number: 8957B Hutchison China Meditech Limited 07 April 2017 Press Release Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 London: Friday, April 7, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintin...

Total Voting Rights

RNS Number: 1321B Hutchison China Meditech Limited 31 March 2017 Total Voting Rights London: Friday , March 31, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary shares of US$1.00 each, wi...

Equity Research (HCM)

edison investment research
Hutchison China MediTech Limited
11/05/2017
Despite a strong run over the last 12 months, our increased valuation of $2.7bn suggests the market overlooks HCM’s full R&D potential. Multiple catalysts are on the horizon in 2017/18; notably...
edison investment research
Hutchison China MediTech Limited
06/03/2017
Hutchison (HCM) and partner Lilly announced positive, top-line pivotal phase III trial results for fruquintinib in 3rd line colorectal cancer. The China based FRESCO study evaluating 416 patients who...
edison investment research
Hutchison China MediTech Limited
27/02/2017
Hutchison (HCM) and partner AstraZeneca presented positive preliminary data from the ongoing phase II proof-of-concept trial evaluating savolitinib (c-Met TKI) in papillary renal cell carcinoma (PRCC...

Latest discussion posts More

  • Update please

    About the forthcoming Chinese FDA application/ approval. I am sure keen followers of chi- med on this board are able to update for the benefit other investors. Also helps to ...
    16-May-2017
    sporty investor
  • Re: Why on AIM?

    This question has been put to the Board at a number of AGM's, although not at the meeting this week. The Company's view seems to be that it has served them well and they do ...
    30-Apr-2017
    David Global
  • Re: Why on AIM?

    Good point, really couldn't answer that for you, people are always asking this question on boards where the company barely makes small cap rating. But HCM is prime candidate ...
    30-Apr-2017
    Maru118

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'27%
NATIONAL GRID25%
LLOYDS GRP.20%
GLAXOSMITHKLINE18%
BP18%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM